Relief as a US-Based Drug Maker Discovers a +90% Effective Covid-19 Vaccine

Relief as a US-Based Drug Maker Discovers a +90% Effective Covid-19 Vaccine

The whole world felt slightly relieved on Monday 9^th November 2020 when Pfizer, a Drug company in US gave its report concerning a possible covid-19 vaccine. The giant drug company reported that from the data they had sampled, the vaccine which has been under test is above 90% effective in preventing Covid-19.  This is good news since the vaccine has just come in at a time when there is a second wave of covid-19 globally. Should the trend in rising cases continue, then the vaccine from Pfizer will be of great aid.

Read also: How to Make a Day Shorter But Productive During This COVID-19 Pandemic

In the interim analysis of the vaccine, more than 43,000 volunteers were grouped into two. The first group was subjected to the Pfizer vaccine while the other half was subjected to a placebo. 10% the infections recorded were from the participants who had been subjected to the Pfizer’s vaccine.90% of the positive cases were from the group that had been subjected to a placebo.

In its report, Pfizer acknowledged its partnership with BioNTech, a giant drug company based in Germany. The reports have it that the vaccine’s efficacy rate is above 90% by the 7^th day after the second dose. This implies that within 28 days of commencing vaccination, the vaccinated person gets protected. Two doses of the vaccine are mandatory, for very effective results.

Pfizer and BioNTech have gone beyond American food and drug administration’s (FAD) expectation, which was only 50% efficacy.

A medical correspondent described the covid-19 vaccine as “the greatest medical advance” in the last century.  “Emotions are very high. You can imagine how I felt when I heard the results yesterday at 2 p.m. I think that likely, based on impact, this will be the greatest medical advance in the last 100 years,” Bourla confirmed.

The drug maestro requested to monitor the volunteers for 60 days when they will administer the second dose of the vaccine, before seeking a green light from FDA to use the vaccine. The drug is projected to be in the market by week 3 of November.